실적분석 2026년 7월 31일

Nano-X Imaging ($NNOX) Q2 2026 Earnings Analysis — Preliminary Revenue Rises, Cash Burn Continues, Final EPS Not Yet Disclosed

Earnings Scorecard

Revenue: Approximately $4.0–$4.1 million (preliminary, unaudited) (about +33% to +37% versus $3.0 million a year earlier; limited consensus makes it difficult to judge against estimates)

EPS (Earnings Per Share): Figure not yet finalized (not included in the preliminary disclosure; final earnings press release unconfirmed)

Guidance: Not provided — after withdrawing the 2026 full-year revenue target in Q1, the company has continued to refrain from issuing full-year revenue guidance

Stock reaction: After-hours -0.52% ($0.96) — as of 7:21 PM Korea time, 07-31

The Positives

Preliminary revenue growth: Q2 preliminary revenue of approximately $4.0–$4.1 million, up about +33–37% from $3.0 million a year earlier

AI and software contribution: Revenue from this segment reached $1.0 million (versus $0.1 million a year earlier), expanding the topline

Commercialization progress: Additional capital equipment contract for the U.S. Nano-X Arc, first installation of the imaging network, and a UK reseller agreement

Nano-X Imaging ($NNOX), a platform company combining medical imaging equipment, teleradiology, and AI software, disclosed preliminary Q2 figures via an SEC filing on July 23. Revenue growth was driven by modest expansion in teleradiology (approximately $2.9 million), combined with a jump in AI and software revenue to $1.0 million, with the company citing the acquisition and integration of USARAD's healthcare IT assets as the primary reason.

On the operational side, the company highlighted commercialization milestones including an additional capital equipment contract for the U.S. Nano-X Arc, the first installation of the imaging network in Philadelphia (preparing for patient scans), and a UK reseller agreement with Vortex for AI-based bone disease solutions. Because this is a small-cap name with thin analyst consensus coverage, year-over-year and segment-level trends are more useful than a "beat versus estimate" framing.

The Negatives

Gap in final profitability figures: Final income-statement items such as EPS and net loss were not included in the preliminary disclosure and remain unconfirmed

Sharp cash decline: Cash and equivalents at the end of June totaled approximately $31.4 million (down from $60.0 million at year-end)

Going-concern disclosure: Under current plans, the company lacks sufficient funding to operate for more than one year, raising substantial doubt about its ability to continue as a going concern

The preliminary disclosure focuses on revenue and cash, and the company stated that because impairment reviews have not yet been completed, final results could differ materially from the preliminary figures. The key numbers investors rely on — EPS, operating loss, and the like — have not yet been finalized or released, representing the most significant information gap.

Cash declined from $60.0 million at the end of 2025 to approximately $31.4 million at the end of June 2026, and management stated that based on the current operating plan, the company does not have enough resources to sustain operations for at least one year from the filing date. Management is pursuing private-placement and capital-markets financing, but noted there is no guarantee of success, and is also considering conditional spending deferrals. Additionally, the company is in a transition period as CFO Ran Daniel steps down effective July 31, placing financial communication continuity among the items to monitor.

What the Company Said

CEO and Interim Chairman of the Board Erez Melcher said the company was encouraged by the commercial and strategic progress made since the previous earnings report, and noted that in Q3 the company would continue focusing on Arc deployments, bringing the imaging network online, and expanding AI business partnerships, while remaining committed to disciplined execution and long-term value. The tone leans more toward "continued execution" than defensiveness, but the same filing body also flags cash shortfalls, going-concern doubt, and incomplete impairment review — so the market is likely to focus on liquidity and the finalization of profitability figures rather than on the optimistic commentary.

The company did not provide next-quarter or full-year revenue or EPS guidance in this preliminary release; this appears to be a continuation of the stance taken in Q1, when the company stated that achieving the 2026 full-year revenue target would be difficult and that it would no longer issue full-year revenue guidance. Investors should not confuse analyst-consensus next-quarter EPS estimates with company-provided guidance.

Market Reaction and What to Watch Next

The muted after-hours move is most naturally explained by the fact that the revenue-growth news had already been priced in via the July 23 preliminary disclosure, while the absence of the "final scorecard" — EPS and impairment treatment — made it difficult to place directional bets. With a small market capitalization compounded by litigation, financing, and CFO transition issues, the stock is trading in a wait-and-see mode where positives and negatives are already embedded in the price.

Watch the final unaudited earnings release to see how EPS, net loss, and impairment treatment compare with the preliminary revenue figures.

Track the pace of further cash burn and any announcements of equity offerings, convertible notes, or other financing arrangements.

Verify in next-quarter metrics whether Arc installations, the first patient scans on the imaging network, and the UK AI reseller arrangement translate into actual revenue and utilization.